HYDROMORPHONE HYDROCHLORIDE INJECTION, USP SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

HYDROMORPHONE HYDROCHLORIDE

Disponibbli minn:

FRESENIUS KABI CANADA LTD

Kodiċi ATC:

N02AA03

INN (Isem Internazzjonali):

HYDROMORPHONE

Dożaġġ:

10MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

HYDROMORPHONE HYDROCHLORIDE 10MG

Rotta amministrattiva:

INTRAMUSCULAR

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Narcotic (CDSA I)

Żona terapewtika:

OPIATE AGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0108698001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2019-08-21

Karatteristiċi tal-prodott

HYDROmorphone Hydrochloride Injection, USP - 2 mg/mL
Page 1 of 34
PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
N
HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
(Hydromorphone Hydrochloride Injection, USP)
2 mg/mL Sterile Solution for Injection
Intramuscular, Intravenous, Subcutaneous
Opioid Analgesic
NOT A PRODUCT MONOGRAPH
Fresenius Kabi Canada Ltd.
Date of revision:
165 Galaxy Blvd. Suite 100
August 20, 2019
Toronto, Ontario
M9W 0C8
Submission Control No.: 212894
HYDROmorphone Hydrochloride Injection, USP - 2 mg/mL
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 3
SUMMARY PRODUCT INFORMATION
........................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................................
3
CONTRAINDICATIONS
...................................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................
12
DRUG INTERACTIONS
..................................................................................................................
15
DOSAGE AND ADMINISTRATION
..............................................................................................
16
OVERDOSAGE
................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
............................................................................
20
STORAGE AND STABILITY
.........................................................................................................
22
SPECIAL HANDLING INSTRUCTIONS
.....................................................